Selected innovation references

Accessible target discovery

Chemical-proteomics methods for identifying disease-associated targets accessible from the vasculature.

01
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature.
Rybak et al., Nat Methods. 2005 Apr;2(4):291-8
PubMed: In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature.
02
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer.
Castronovo et al., Mol Cell Proteomics. 2006 Nov;5(11):2083-91
PubMed: A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer.
03
Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method.
Castronovo et al., Proteomics. 2007 Apr;7(8):1188-96
PubMed: Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method.

Antibody-phage and DNA-encoded chemical-library technologies used to discover targeting ligands.

01
Design, construction, and characterization of a large synthetic human antibody phage display library.
Silacci et al., Proteomics. 2005 Jun;5(9):2340-50
PubMed: Design, construction, and characterization of a large synthetic human antibody phage display library.
02
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Wichert et al., Nat Chem. 2015 Mar;7(3):241-9
PubMed: Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
03
Flexibility-tuning of dual-display DNA-encoded chemical libraries facilitates cyclic peptide ligand discovery.
Petrov et al., Nat Commun. 2025 Apr 5;16(1):3273
PubMed: Flexibility-tuning of dual-display DNA-encoded chemical libraries facilitates cyclic peptide ligand discovery.

Selected platform and product publications on targeted delivery of immunomodulatory cytokines.

01
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
Hutmacher et al., Adv Drug Deliv Rev. 2019 Feb 15;141:67-91
PubMed: Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
02
Tripokin: A multi-specific immunocytokine for cancer immunotherapy.
Prodi et al., Int J Cancer. 2025 Jan 1;156(1):216-228
PubMed: Tripokin: A multi-specific immunocytokine for cancer immunotherapy.
03
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.
Kähler et al., Ann Oncol. 2025 Jul 7:S0923-7534(25)00829-4
PubMed: Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Selected publications on FAP-, ACP3- and CAIX-targeted drug and radionuclide delivery.

01
Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
Galbiati et al., J Nucl Med. 2024 Oct 1;65(10):1604-1610
PubMed: Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
02
Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.
Georgiev et al., Nat Biomed Eng. 2025 Jun 26
PubMed: Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.
03
Small Organic Carbonic Anhydrase IX Ligands from DNA-Encoded Chemical Libraries for Tumor-Targeted Delivery of Radionuclides.
Müller et al., J Am Chem Soc. 2025 May 28;147(21):18230-18239
PubMed: Small Organic Carbonic Anhydrase IX Ligands from DNA-Encoded Chemical Libraries for Tumor-Targeted Delivery of Radionuclides.
04
Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics.
Bocci et al., Mol Cancer Ther. 2025 Jun 30
PubMed: Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics.